Travere, Ligand Pharma announce FDA label expansion for Filspari
Source: SeekingAlpha
2026-04-14 07:53:56 ET
More on Travere Therapeutics, Ligand Pharmaceuticals
- Travere Therapeutics, Inc. (TVTX) Discusses FDA Approval of FILSPARI as First Approved Medicine for FSGS Transcript
- Travere Therapeutics, Inc. (TVTX) Discusses FDA Approval of FILSPARI as First Approved Medicine for FSGS - Slideshow
- Ligand Pharmaceuticals: Reliable Midcap Pharma With Perfected High Growth Business Model
- Ligand gains new Buy from BofA on high-margin, less risky narrative
- Ligand outlines 23% CAGR royalty growth outlook through 2030 as royalty portfolio accelerates
Read the full article on Seeking Alpha
For further details see:
Travere, Ligand Pharma announce FDA label expansion for Filspari
Ligand Pharmaceuticals Incorporated
NASDAQ: LGND
LGND Trading
-1.0% G/L:
$286.215 Last:
149,830 Volume:
$291.48 Open:
LGND Latest News
June 23, 2026 04:00:00 am
Ligand Announces Pricing of Upsized $625 Million Convertible Senior Notes Offering
June 22, 2026 07:00:00 am
Ligand Announces Proposed Offering of $550 Million of Convertible Senior Notes Due 2031
June 14, 2026 07:20:01 am
Ligand Pharmaceuticals Director Unloads 2,501 Shares - Should You Be Concerned?
$3,626,553,727
18,304,000
0.22%
151
N/A
Biotechnology & Life Sciences
Healthcare
US
Jupiter
